Regeneron Stock – Sandoz Begins Late-Stage Clinical Development for Biosimilar Aflibercept
Regeneron Stock - Sandoz Begins Late-Stage Clinical Development for Biosimilar Aflibercept Sandoz will soon begin enrolling patients with neovascular age-related ...